Skip to main content
SpringerLink
Log in

Sicherung des onkologischen Therapieerfolgs durch Supportivtherapie

Dermale Toxizität durch EGFR-Inhibitoren

  • Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Reagiert die Haut unter anderem mit Exanthemen auf eine Therapie, die den Rezeptor des epidermalen Wachstumsfaktors hemmt, ist dies ein gutes Zeichen für den Behandlungserfolg. Trotzdem leiden die Patienten unter der Toxizität. Wie lässt sie sich in den Griff bekommen?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1:
Abb. 2:

Literatur

  1. Atherton PJ et al. Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care Cancer. 2011 Sep 16. [Epub ahead of print].

  2. Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004. 351(4):337–45.

    Article  CAS  PubMed  Google Scholar 

  3. Gerber PA et al. More on aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010; 364(5):486–7.

    Google Scholar 

  4. Gutzmer R et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges. 2011;9(3):195–203.

    PubMed  Google Scholar 

  5. Jatoi A et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Supp Care Cancer. 2011.19(10): 1601–7.

    Article  Google Scholar 

  6. Jatoi A et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. 2008;113(4):847–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lacouture ME et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supp Care Cancer. 2011;19(8):1079–95.

    Article  Google Scholar 

  8. Lacouture ME et al. Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a phase II, open-label, randomised trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2011;28:1351–7.

    Article  CAS  Google Scholar 

  9. Leveque D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363(17):1680–1; author reply 1681.

    Article  PubMed  Google Scholar 

  10. Mir OB et al. More on aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;364(5):487.

    Google Scholar 

  11. Perez-Soler R et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004. 22(16):3238–47.

    Article  CAS  PubMed  Google Scholar 

  12. Potthoff K et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011;22(3):524–35.

    Article  CAS  PubMed  Google Scholar 

  13. Rowinsky EK et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004;22(15):3003–15.

    Article  CAS  PubMed  Google Scholar 

  14. Saltz LB et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201–8.

    Article  CAS  PubMed  Google Scholar 

  15. Santini D et al. J Clin Oncol. 2011; 29 (suppl; abstr 9078).

    Google Scholar 

  16. Scope A et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25(34): 5390–6.

    Article  CAS  PubMed  Google Scholar 

  17. Vincenzi B et al. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363(4): 397–8.

    Article  CAS  PubMed  Google Scholar 

  18. Wacker B et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13(13):3913–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Innere Medizin IV Onkologie/Hämatologie/Hämostaseologie Universitätsklinikum Halle, Ernst-Grube-Str. 40, 06120, Halle/Saale, Deutschland

    Timo Behlendorf

  2. Halle, Deutschland

    Danica Lange &  Karin Jordan

Authors
  1. Timo Behlendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danica Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karin Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timo Behlendorf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Behlendorf, T., Lange, D. & Jordan, K. Sicherung des onkologischen Therapieerfolgs durch Supportivtherapie. Im Focus Onkologie 15, 56–60 (2012). https://doi.org/10.1007/s15015-012-0048-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-012-0048-8

Search

Navigation